English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/6252
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 25 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título : Adipose tissue mass is modulated by SLUG (SNAI2)
Autor : Pérez-Mancera, P. A.; Bermejo-Rodríguez, C.; González-Herrero, Inés; Flores, Teresa; Jiménez, Rafael; Sánchez García, Isidro
Fecha de publicación : 2007
Editor: Oxford University Press
Citación : Human Molecular Genetics 16(23): 2972-2986 (2007)
Resumen: The zinc-finger transcription factor SLUG (SNAI2) triggers epithelial–mesenchymal transitions (EMTs) and plays an important role in the developmental processes. Here, we show that SLUG is expressed in white adipose tissue (WAT) in humans and its expression is tightly controlled during adipocyte differentiation. Slug-deficient mice exhibit a marked deficiency in WAT size, and Slug-overexpressing mice (Combi-Slug) exhibit an increase in the WAT size. Consistent with in vivo data, Slug-deficient mouse embryonic fibroblasts (MEFs) showed a dramatically reduced capacity for adipogenesis in vitro and there was extensive lipid accumulation in Combi-Slug MEFs. The analysis of adipogenic gene expression both in vivo and in vitro showed that peroxisome proliferator-activated factor 2 (PPAR2) expression was altered. Complementation studies rescued this phenotype, indicating that WAT alterations induced by Slug are reversible. Our results further show a differential histone deacetylase recruitment to the PPAR2 promoter in a tissue- and Slug-dependent manner. Our results connect, for the first time, adipogenesis with the requirement of a critical level of an EMT regulator in mammals. This work may lead to the development of targeted drugs for the treatment of patients with obesity and/or lipodystrophy.
Descripción : 15 páginas, 13 figuras, 1 tabla.
Versión del editor: http://dx.doi.org/10.1093/hmg/ddm278
URI : http://hdl.handle.net/10261/6252
DOI: 10.1093/hmg/ddm278
ISSN: 0964-6906
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.